Cells4Life Establishes Robust Stem Cell Viability Testing
News Dec 13, 2007
Cells4Life Ltd has, using a Personal Cellular Analysis (PCA) system from Guava Technologies Inc., established a robust testing protocol for all umbilical cord blood samples upon arrival at its laboratory before freezing.
Using the Guava® PCA system, Cells4Life is able to ensure that only samples containing a high percentage of viable (living) cells are cryopreserved for storage.
Jeff Drew, Chief Scientist at Cells4Life said, “Without the Guava® PCA system, counting of nucleated cells would be a manual process, which would be very costly in labour terms and also prone to personnel variances”. He added “The Guava® PCA system has increased the speed and reliability of our in-house viability testing and it also usefully provides a hard copy report in a format easily understood by non-technical staff and customers”.
The ultra-compact size makes the Guava® PCA system indispensable to all scientists who need immediate access to simple cell monitoring and screening assays. Intuitive in operation, the Guava® PCA can provide precise and easy-to-read results with often less than one day of training.
Increased cell counting accuracy on the Guava® PCA translates into evaluation of percentage viable stem cells in samples prior to cryopreservation. Benefiting from a patented self-aligning, user-replaceable microcapillary flow cell - assays on the Guava® PCA need less cells (< 20 µl), less reagents and generate minimal waste.
Regenerative Medicine Meets Clever Engineering to Accommodate Bone GraftsNews
Personalized bone grafts developed to repair bone defects from disease or injuryREAD MORE
Protein Essential for Making Stem Cells IdentifiedNews
The discovery by Stanford scientists drills a peephole into the black box of cellular reprogramming and may lead to new ways to generate induced pluripotent stem cells in the laboratory.READ MORE
3D Super-Resolution Nanoscopes Used To Identify Amyloid PlaquesNews
A new development in 3D super-resolution imaging gives insight on Alzheimer's diseaseREAD MORE